Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cambrex and Tillotts Pharma have signed a development and commercialization deal for mesalamine-based (5-ASA) technology to use it in the treatment of inflammatory bowel disease (IBD).
Subscribe to our email newsletter
As per the terms of the agreement, Cambrex has sold the development and commercialization rights for the drug products to Tillotts which are based on 5-ASA-based technology.
In connection to that, Cambrex will get developmental, regulatory and IP milestone payments as well as royalties from Tillotts.
Tillotts president and CEO Thomas Toth von Kisker said this deal, which gives Tillotts worldwide access to proprietary 5-ASA-based technology, is an additional important step in their efforts over the years to come to build gastrointestinal product portfolio, complementary to their Asacol and Colpermin.